EcoDrugPlus

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSNFUG00015003243
Gene Symbol: NR3C1
1 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSNFUG00015002863
Gene Symbol: NR3C2
1 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSNFUG00015005451
Gene Symbol: NOD2
1 Cross references
166 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSNFUG00015018211
Gene Symbol: OPRL1
1 Cross references
176 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSNFUG00015006448
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSNFUG00015000439
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSNFUG00015006954
Gene Symbol: OXTR
3 Cross references
183 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSNFUG00015019969
Gene Symbol: OXTRA
1 Cross references
191 Possible Orthologues:

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSNFUG00015008541
Gene Symbol: PAK4
1 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSNFUG00015011505
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSNFUG00015003005
Gene Symbol: PPARA
3 Cross references
383 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSNFUG00015004713
Gene Symbol: PPARG
3 Cross references
386 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).